Drug makers including Merck & Co., Johnson & Johnson and Bristol-Myers Squibb Co/Gilead have been racing to come up with new treatments for Hepatitis C.
Telaprevir is co-developed by Vertex and Johnson&Johnson. Telaprevir shows promising results in Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. Vertex Pharma is developing telaprevir in collaboration with Tibotec (J&J) and Mitsubishi Tanabe Pharma. (Link). Update: on 23/05/2011, US FDA has approved Telaprevir.
Merck currently developing Boceprevir for the treatment of Hepatitis C. Boceprevir is originally developed by Schering-Polugh. Regulatory submission of Boceprevir is expected by 2010 end in US FDA and EMEA. (Link)
Update: Boceprevir is approved (as on 14/05/2011) by US FDA and this product seems to be protected in India by 206985 (89/CHENP/2003) and 229230 (1564/CHENP/2004).
Boehringer and Gilead also develops new therapy for treating Hepatitis C. Boehringer’s New protease-polymerase inhibitor combination resulted in 73-100% rapid virological responses without pegylated interferon (Link) and Gilead also announced that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment. (Link)